ERBB2 and breast carcinoma: Previously, monoclonal antibodies like Trastuzumab (Herceptin®) (92) and Pertuzumab (Perjeta®) (93), targeting the extracellular domain (ECD) of HER2, have effectively improved overall survival rates in patients with HER2-positive breast cancer (94).